A Service of the National Health Information Center, U.S. Department of Health & Human Services
healthfinder® home page
        Help | Advanced Search
 News Library Just For You Health Care Organizations en Español
Health & Human Services Home Page

Home > News


Health Highlights: April 9, 2004

  • E-mail this article
  • Subscribe to news
  • Here are some of the latest health and medical news developments, compiled by editors of HealthDay:

    Chicago Drugstores Plagued by Pricing Errors: Report

    More than three out of four of Chicago's chain drugstores overcharged customers for their purchases due to mistakes at the checkout counter, the Chicago Tribune reported Friday.

    However, an investigation by the Chicago Department of Consumer Services found no evidence that the overcharges at more than 100 Walgreen's, Osco, and CVS stores were deliberate, the newspaper said.

    Most of the overcharges were between 50 cents and $2, although they ranged from a penny to $45, the investigators found. Experts cited by the newspaper said many customers didn't notice the discrepancies because prices often weren't listed on the items themselves, just on the store shelves.

    While spokespeople for the drugstore chains said many perceived scanner mistakes stemmed from employee failure to correct aisle signs following a sale, the investigators considered the price posted near the item to be what customers should have been charged, the Tribune reported. Also, items similar in appearance can frequently be misplaced under a price sign that represents a different item, industry observers told the newspaper.

    An unnamed city spokesman told the Tribune that the city is in the early stages of investigating the matter.

    -----

    Children Should Avoid Antidepressants: Researchers

    People younger than 18 should avoid newer antidepressants like Paxil and Zoloft because the drugs offer little benefit to this age group and pose "disturbing shortcomings," according to a HealthDay report on an Australian study.

    In the April 10 issue of the British Medical Journal, the researchers concluded that the medications "cannot confidently be recommended as a treatment option for childhood depression."

    Their pronouncement follows a move last month by the U.S. Food and Drug Administration instructing the makers of 10 antidepressants to add a visible warning on the drug label indicating the potential for suicidal thinking and behavior.

    The authors of the new review examined six randomized controlled trials of newer antidepressants -- Effexor, Prozac, Paxil, and Zoloft -- that had been published in refereed journals. They concluded that the benefits were exaggerated and that the side effects -- including suicidal thoughts -- were not well-documented. The researchers added that the studies were sometimes funded by the drugmakers.

    Practicing psychiatrists and other critics of the study, however, dismissed its conclusions. They claimed that the authors of the review never adequately delineated what the serious adverse effects are, and that funding by pharmaceutical companies does not necessarily compromise a study's results.

    -----

    Experimental Drug May Prevent Irregular Heartbeat

    Researchers say they have found a medication to correct the cause of a deadly type of irregular heartbeat in people with heart failure, according to HealthDay.

    About half of the deaths related to heart failure are caused by arrhythmia, a fast and erratic heartbeat. Columbia University Medical Center researchers discovered the cause of that problem more than three years ago, according to lead researcher Dr. Andrew Marks, the schools' chairman of physiology and cellular biophysics. It is a leakiness of the cellular channels through which calcium flows to control the regular beating of the heart. That leakage can result in a fatal arrhythmia.

    In the April 9 issue of the journal Science, the researchers reported that a new drug, designated JTV519, makes a protein that attaches itself to the leaky calcium channels, closing them to stop the leakage. In laboratory tests, the drug prevented arrhythmias in 10 mice with the same molecular defect found in human heart failure, while eight of nine mice with the same defect who did not get the drug developed fatal arrhythmias.

    Heart failure, which affects an estimated 4.6 million Americans and contributes to 300,000 deaths a year, is a progressive loss of the heart's ability to pump blood. Drugs can help many patients, but the ultimate treatment often involves more drastic measures such as implanted defibrillators or heart transplants.

    -----

    Flaws Seen in West Nile Blood Screening

    After noticing that people were contracting West Nile virus through blood transfusions in 2002, U.S. health officials began screening donations in 2003. While that prevented many infections, the government reported Thursday, some still got West Nile from donated blood.

    The number was small, but it was enough to prompt the U.S. Centers for Disease Control and Prevention to call for changes in blood screening this year.

    The CDC reported that the screening method identified more than 800 donations containing West Nile from a total of 6 million units, which the agency said prevented more than 1,000 infections through transfusions. Still, six people got the virus from donated blood.

    According to a report in the CDC publication Morbidity and Mortality Weekly Report, the blood was screened, but viral concentrations were so low that the test didn't detect them. Officials plan to have more sensitive tests later this year, but in the meantime they said that the risk of getting the virus is much lower than the danger in not getting a blood transfusion.

    -----

    Recall of Painkiller Patch Widened

    Janssen Pharmaceutica has announced what the company called an "urgent" expansion of its recall of its painkiller patch Duragesic because of a leak that could cause life-threatening complications.

    Janssen originally announced the recall of one batch in February, but now the recall has widened to four more batches.

    The transdermal patches contain the opioid fentanyl in gel form. The company discovered that a seal along one edge allowed the drug to leak onto the skin. As a result, users could either be not getting enough, which can lead to withdrawal systems, or too much, which can lead to dangerous overdoses.

    The recall applies to Duragesic patches releasing 75 micrograms per hour. The control numbers listed on the package are: 0327192, 0327193, 0327294, 0327295, and 0330362. Patients and caregivers who are exposed to the gel are urged to wash their hands with water only; soap should not be used.

    -----

    Flu Season Petered Out After Early Start

    The 2003-2004 flu season got off to a jackrabbit start, prompting a run on a short supply of vaccine, but it also peaked earlier than usual and appeared to be no more deadly than an average season.

    The U.S. Centers for Disease Control and Prevention said Thursday that the season just ended "was more severe than the previous three seasons," but it was comparable to many seasons in the 1990s, in which similar strains of the flu virus circulated.

    The season started early, in October, and anecdotal reports found that the virus was especially harsh on children. CDC officials said that flu killed 142 children this past season, but could not say whether that was unusually high, since this was the first year epidemiologists collected such numbers.

    In December, CDC Director Dr. Julie Gerberding went so far as to call the flu an "epidemic," but by January the number of cases and deaths fell sharply.

    Copyright © 2004 ScoutNews, LLC. All rights reserved.

    HealthDayNews articles are derived from various sources and do not reflect federal policy. healthfinder® does not endorse opinions, products, or services that may appear in news stories. For more information on health topics in the news, visit the healthfinder® health library.
    About Us  Accessibility  Disclaimer  Freedom of Information Act  Privacy  Contact Us
    Office of Disease Prevention and Health Promotion, U.S. Department of Health & Human Services